Biotechnology and healthcare: where we are in India, and where we need to go
Must read — 2 past UPSC questions on this theme (Mains GS-3 2018, Mains GS-3 2021).
2-minute summary
India's biotechnology sector has emerged as a major growth pillar, valued at over $195 billion, driven by advancements in biologics, biosimilars, genomics, diagnostics, and cell and gene therapies. The convergence of biology with artificial intelligence (AI), data analytics, and advanced bioprocessing has transformed biotech from a purely laboratory discipline into a multidisciplinary engine for healthcare, agriculture, and industrial manufacturing. Key indigenous milestones include the development of Covaxin, affordable CAR-T cell therapy, and novel antibiotics like Zaynich. Institutional facilitators like the Biotechnology Industry Research Assistance Council (BIRAC) and strategic frameworks like the BioE3 Policy are pivotal in nurturing startups, fostering intellectual property, and driving precision biotherapeutics. However, challenges persist in bridging the gap between academia, industry, and hospitals to translate research into scalable products, requiring deeper focus on core med-tech innovation, synthetic biology, and robust biomanufacturing capabilities to reduce import dependence and expand global competitiveness.
Why it's in the news
The biotechnology sector is highlighted as a national growth pillar crucial for improving healthcare access, reducing import dependency, boosting domestic manufacturing, and generating high-value employment, supported by emerging policies like the BioE3 Policy and institutional scaling.
Facts to remember
- India's biotechnology sector has emerged as a major growth pillar valued at over $195 billion.
- Key indigenous milestones in the biotech sector include the development of Covaxin, affordable CAR-T cell therapy, and novel antibiotics like Zaynich.
- The Department of Biotechnology (DBT) was established in 1986 under the Ministry of Science and Technology.
- The Genome India initiative aims to sequence 10,000 Indian human genomes to build a reference database for precision medicine and genetic disease research.
Background and context
India's biotechnology sector has evolved significantly from its early days in the 1970s as a basic laboratory science into a globally competitive bioeconomy. The establishment of the Department of Biotechnology (DBT) under the Ministry of Science and Technology in 1986 served as the foundational institutional push. Over the decades, India transitioned from a reverse-engineering pharmaceutical hub to a leader in vaccine manufacturing, earning the title of the 'pharmacy of the world' during the COVID-19 pandemic through the rapid scaling of indigenous vaccines like Covaxin. Recent strategic initiatives, such as the BioE3 (Biotechnology for Economy, Environment and Employment) Policy and the Genome India initiative, mark a paradigm shift toward advanced precision biotherapeutics, synthetic biology, and AI-enabled biomanufacturing, aiming to position India as a global bio-manufacturing powerhouse.
Government schemes
- BioE3 Policy (Biotechnology for Economy, Environment and Employment) — Identifies priority areas including precision biotherapeutics, bio-based APIs, enzymes, functional foods, and Bio-AI-enabled biomanufacturing to foster high-performance biomanufacturing.
- Genome India Initiative — Aims to sequence 10,000 Indian human genomes to build a reference database for precision medicine and genetic disease research.
Previous UPSC questions on this theme
- Mains GS-3 2018 — Why is there so much activity in the field of biotechnology in our country? How has this activity benefitted the field of biopharma?
- Mains GS-3 2021 — What are the research and developmental achievements in applied biotechnology? How will these achievements help to uplift the poorer sections of the society?
Mains practice: Discuss the potential of biotechnology in transforming India's healthcare landscape. What are the key bottlenecks in scaling the domestic bioeconomy, and how can they be addressed?
Introduction:
India's bioeconomy, valued at over $195 billion, is rapidly transitioning from a generic pharmaceutical hub into a advanced healthcare-biotech ecosystem driven by biologics, biosimilars, genomics, and cell and gene therapies.
Body:
• Potential in Healthcare: Indigenous advancements such as CAR-T cell therapy, novel antibiotics like Zaynich, and rapid vaccine manufacturing (e.g., Covaxin) demonstrate India's capacity to deliver affordable, high-end medical innovations. Precision biotherapeutics and AI-enabled drug discovery are revolutionizing cancer care and rare disease management.
• Policy & Institutional Support: Frameworks like the BioE3 Policy and agencies like BIRAC have successfully catalyzed startups, intellectual property creation, and commercialization.
• Bottlenecks to Scale:
- Translation Gap: Weak links between academia, industry, hospitals, and policymakers impede the translation of bench discoveries to bedside applications.
- Core Med-Tech Deficit: Heavy reliance on IT and software solutions rather than core hardware and deep-tech medical device manufacturing.
- Infrastructure & Biomanufacturing: High capital requirements for clinical trials, advanced bioprocessing, and specialized supply chains.
• Way Forward:
- Strengthening the Triple Helix model: Fostering active collaboration between research institutions, industry stakeholders, and clinical settings.
- Targeted R&D funding and fiscal incentives for synthetic biology and bio-based APIs to reduce import dependence.
- Streamlining regulatory pathways to accelerate approvals for indigenous medical innovations without compromising safety.
Conclusion:
By leveraging its robust scientific talent and integrating artificial intelligence with biology, India can unlock the full potential of its bioeconomy, ensuring equitable healthcare access and establishing global leadership in biomanufacturing.
Prelims practice questions
Q1. Consider the following statements regarding the Biotechnology Industry Research Assistance Council (BIRAC): 1. It is a not-for-profit public sector enterprise set up by the Department of Biotechnology (DBT). 2. Its primary mandate is to strengthen and empower emerging biotech enterprises to undertake strategic research and innovation. Which of the statements given above is/are correct?
- 1 only
- 2 only
- Both 1 and 2
- Neither 1 nor 2
Answer: C. BIRAC is a not-for-profit Section 8 Public Sector Enterprise, set up by the Department of Biotechnology (DBT), Government of India, to nurture and foster the biotech innovation ecosystem in the country.
Q2. With reference to recent trends in biotechnology, the term 'Synthetic Biology' is best described as:
- The process of extracting natural medicinal compounds from endangered medicinal plants.
- The large-scale commercial cultivation of genetically modified crops for biofuel production.
- A computational method exclusively used for mapping human chromosomes and gene editing via CRISPR.
- The design and construction of new biological parts, devices, and systems that do not exist in nature.
Answer: D. Synthetic biology is a multidisciplinary field of science that focuses on living systems and organisms, applying engineering principles to design and construct new biological parts, devices, and systems (or redesign existing natural biological systems).
Q3. The 'BioE3 Policy', recently seen in news regarding priority areas like precision biotherapeutics and bio-based APIs, stands for:
- Biotechnology for Economy, Ecology, and Education
- Bio-Energy, Environment, and Economic Empowerment
- Biotechnology for Economy, Environment and Employment
- Bio-Engineering, Ethics, and Epigenetics Enterprise
Answer: C. The BioE3 Policy stands for Biotechnology for Economy, Environment and Employment, focusing on high-performance biomanufacturing, precision biotherapeutics, and sustainable industrial solutions.
Revision flashcards
- What is the primary objective of the Genome India Initiative? To sequence 10,000 Indian human genomes to create a comprehensive reference database for understanding genetic variations and advancing precision medicine.
- What is BIRAC's role in India's biotech ecosystem? BIRAC (Biotechnology Industry Research Assistance Council) acts as an ecosystem builder, supporting startups and incubators, generating IP/patents, and enabling commercialization of indigenous biotech products.
- What are precision biotherapeutics as highlighted under the BioE3 Policy? They include advanced medical interventions such as monoclonal antibodies, mRNA therapeutics, and cell and gene therapies targeted at specific molecular profiles.
- What is the significance of Zaynich in India's pharmaceutical context? Zaynich is an indigenously developed antibiotic by Wockhardt that received approval for use in the United States, demonstrating India's growing capability in novel drug development.
- Which government department administers the policies related to biotechnology in India? The Department of Biotechnology (DBT), operating under the Ministry of Science and Technology.